Clark Golestani has over 30 years of experience in health, life sciences and technology, and is an active investor, advisor and board member with a focus on the healthcare, life science and technology, media, and telecommunications (TMT) sectors. Mr. Golestani currently serves as the managing director of C Sensei Group, LLC an advisory services firm, as a senior advisor to New Mountain Capital based in New York City, NY, as an investment advisor to The CXO Fund based in Palo Alto, CA, a special advisor to the Dean at the University of Texas at Austin, Dell Medical School, and as a member of the DIA – Science and Policy Advisory Council.
Mr. Golestani actively advises companies, private equity and venture funds across healthcare, life sciences and horizontal technology sectors spanning company, go-to-market, data, digital, technology, and transformation strategies. Mr. Golestani serves as chairman of the board for Sparta Systems, the world’s premier provider of cloud and on-premise quality management software; and as an independent director on the board of directors for CIOX Health, the leading provider of health information management and exchange across the United Sates; eMids, a leading provider of digital transformation solutions to the healthcare industry, serving payers, providers, life sciences, and technology firms; TruU, Inc., the leading provider of converged security services that leverages AI, biometrics, and user behavior to provide a trusted user identity that can seamlessly migrate across digital and physical mediums; UMUC/Ventures, a not-for-profit organization established by the University of Maryland University College (UMUC), that develops innovative businesses and partnerships, supporting efforts to reduce the cost of higher education for adult learners while addressing the workforce needs of the 21st century; and Zapata Computing, the leading provider of quantum computing software and algorithms to solve industry-critical problems.
Mr. Golestani retired from Merck in 2018 as the President, Emerging Businesses and Global CIO, with responsibilities for Merck’s portfolio of digital health services and solutions companies inclusive of the company’s venture and equity funds – each of which extensively leverages opportunities across the digital health ecosystem. Further, Mr. Golestani led the company’s global Information Technology organization, strategy, and execution worldwide, spanning all lines of business inclusive of Human Health and Animal Health BioPharma. Prior to joining Merck, Mr. Golestani was responsible for establishing and managing strategic client relationships from business development through consulting services engagement delivery as a principal with Oracle.
Previously, Mr. Golestani served on the Board of Directors for Liaison Technologies acquired by Open Text Corporation, NPower, and Seal Software acquired by Docusign. He has a degree in Management Science from the Massachusetts Institute of Technology Sloan School of Management, and is a cofounder of Cross Road Technologies, Inc., in Cambridge, Massachusetts.